Survival Benefit of Intraductal Radiofrequency Ablation for Malignant Biliary Obstruction: A Systematic Review with Meta-Analysis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Cholangiocarcinoma (CCA) is a rare but aggressive disease with a poor survival. Recent trials have shownimproved survival with intraductal radiofrequency ablation (RFA) therapy. We performed a systematic review with meta-analysis todetermine the survival benefit of endoscopic RFA for unresectable extrahepatic CCA with malignant biliary obstruction (MBO). Methods: A systematic search from 1970 to 2020 was performed in MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials. gov. We selected eligible studies reporting relative risks, hazard ratios (HRs), or odds ratios, adjusted by controlling for confoundingfactors of survival rate and stent patency duration, among patients with extrahepatic CCA with MBO treated with RFA with stentinsertion or stent insertion only. Results: A total of eight trials (three randomized and five nonrandomized) with a total of 420 patients were included in the metaanalysis. Pooled overall survival analysis favored RFA treatment with stent insertion (HR, 0.47; 95% confidence interval [CI], 0.34–0.64; I2=47%; p=0.09); however, no significant difference was found in the duration of stent patency between the groups (HR, 0.79;95% CI, 0.57–1.09; I2=7%; p=0.36). Conclusions: RFA therapy with stent insertion may confer a survival benefit compared with stent insertion only in patients withCCA and MBO.
Abstract
Background/Aims: Cholangiocarcinoma (CCA) is a rare but aggressive disease with a poor survival. Recent trials have shownimproved survival with intraductal radiofrequency ablation (RFA) therapy. We performed a systematic review with meta-analysis todetermine the survival benefit of endoscopic RFA for unresectable extrahepatic CCA with malignant biliary obstruction (MBO). Methods: A systematic search from 1970 to 2020 was performed in MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials. gov. We selected eligible studies reporting relative risks, hazard ratios (HRs), or odds ratios, adjusted by controlling for confoundingfactors of survival rate and stent patency duration, among patients with extrahepatic CCA with MBO treated with RFA with stentinsertion or stent insertion only. Results: A total of eight trials (three randomized and five nonrandomized) with a total of 420 patients were included in the metaanalysis. Pooled overall survival analysis favored RFA treatment with stent insertion (HR, 0.47; 95% confidence interval [CI], 0.34–0.64; I2=47%; p=0.09); however, no significant difference was found in the duration of stent patency between the groups (HR, 0.79;95% CI, 0.57–1.09; I2=7%; p=0.36). Conclusions: RFA therapy with stent insertion may confer a survival benefit compared with stent insertion only in patients withCCA and MBO.
참고문헌 (26)
- Vauthey JN, "Recent advances in the management of cholangiocarcinomas", Semin Liver Dis, 14, pp.109~114 (1994)
- Global Burden of Disease Cancer Collaboration, "The global burden of cancer 2013", JAMA Oncol, 1, pp.505~527 (2015)
- Patel N, "Incidence of cholangiocarcinoma in the USA from 2001 to 2015: A US cancer statistics analysis of 50 states", Cureus, 11, pp.e3962~ (2019)
- Zografos GN, "Cholangiocarcinoma : principles and current trends", Hepatobiliary Pancreat Dis Int, 10, pp.10~20 (2011)
- Esnaola NF, "Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma", Cancer, 122, pp.1349~1369 (2016)
- Mihalache F, "Survival and quality of life of cholangiocarcinoma patients : a prospective study over a 4 year period", J Gastrointestin Liver Dis, 19, pp.285~290 (2010)
- Yang J, "Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma : a randomized trial", Endoscopy, 50, pp.751~760 (2018)
- Hu B, "Endobiliary radiofrequency ablation improve overall survival of cholangiocarcinoma : a multi-center randomized control study", Gastrointest Endosc, 83(5 Suppl), pp.AB126~ (2016)
- Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
- Sterne JA, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions", BMJ, 355, pp.i4919~ (2016)
- Kang H, "Efficacy and safety of palliative endobiliary radiofrequency ablation using a novel temperature-controlled catheter for malignant biliary stricture : a single-center prospective randomized phase II TRIAL", Surg Endosc, 35, pp.63~73 (2021)
- Sharaiha RZ, "Comparison of metal stenting with radiofrequency ablation versus stenting alone for treating malignant biliary strictures : is there an added benefit?", Dig Dis Sci, 59, pp.3099~3102 (2014)
- Kallis Y, "Analysis of endoscopic radiofrequency ablation of biliary malignant strictures in pancreatic cancer suggests potential survival benefit", Dig Dis Sci, 60, pp.3449~3455 (2015)
- Wang J, "Percutaneous intraductal radiofrequency ablation combined with biliary stent placement for nonresectable malignant biliary obstruction improves stent patency but not survival", Medicine (Baltimore), 95, pp.e3329~ (2016)
- Dutta AK, "Radiofrequency ablation for management of malignant biliary obstruction : a single-center experience and review of the literature", Expert Rev Gastroenterol Hepatol, 11, pp.779~784 (2017)
- Bokemeyer A, "Endoscopic radiofrequency ablation prolongs survival of patients with unresectable hilar cholangiocellular carcinoma-a case-control study", Sci Rep, 9, pp.13685~ (2019)
- Tierney JF, "Practical methods for incorporating summary time-to-event data into meta-analysis", Trials, 8, pp.16~ (2007)
- Higgins JP, "Measuring inconsistency in meta-analyses", BMJ, 327, pp.557~560 (2003)
- Loew BJ, "Comparative performance of uncoated, self-expanding metal biliary stents of different designs in 2diameters : final results of an international multicenter, randomized, controlled trial", Gastrointest Endosc, 70, pp.445~453 (2009)
- Goldberg SN, "Radiofrequency tissue ablation : physical principles and techniques for increasing coagulation necrosis", Hepatogastroenterology, 48, pp.359~367 (2001)
- Steel AW, "Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction", Gastrointest Endosc, 73, pp.149~153 (2011)
- Hansler J, "Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases", World J Gastroenterol, 12, pp.3716~3721 (2006)
- den Brok MH, "In situ tumor ablation creates an antigen source for the generation of antitumor immunity", Cancer Res, 64, pp.4024~4029 (2004)
- Tal AO, "Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction", World J Gastrointest Endosc, 6, pp.13~19 (2014)
- Jason Roque, "Endoscopic Ablation Therapy for Biliopancreatic Malignancies", Clinical Endoscopy, 48(1), pp.15~19 (2015), 대한소화기내시경학회
- Dolak W, "Endoscopic radiofrequency ablation for malignant biliary obstruction : a nationwide retrospective study of 84 consecutive applications", Surg Endosc, 28, pp.854~860 (2014)